Bithiazole carboxylic acid | 933742-50-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: Bithiazole carboxylic acid
• 英文别名: 2-(1,3-thiazol-2-yl)-1,3-thiazole-4-carboxylic acid
• CAS: 933742-50-8
• 化学式: C₇H₄N₂O₂S₂
• 分子量: 212.253
• InChiKey: BSWWUUBLFASJQT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  120
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  Bithiazole carboxylic acid 在 盐酸羟胺 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 、 potassium hydroxide 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 13.0h， 生成 N-[5-(hydroxyamino)-5-oxopentyl]-2-(1,3-thiazol-2-yl)-1,3-thiazole-4-carboxamide
  参考文献：
  名称：

  Potent and Orally Efficacious Bisthiazole-Based Histone Deacetylase Inhibitors

  摘要：

  Inspired by the thiazole thiazoline cap group in natural product largazole, a series of structurally simplified bisthiazole-based histone deacetylase inhibitors were prepared and evaluated. Compound 8f was evaluated in vivo in an experimental autoimmune encephalomyelitis (EAE) model and found to be orally efficacious in ameliorating clinical symptoms of EAE mice.

  DOI：

  10.1021/ml400470s
• 作为产物：
  描述：

  Ethyl 2-(1,3-thiazol-2-yl)-1,3-thiazole-4-carboxylate 在 水 、 sodium hydroxide 作用下， 以 甲醇 为溶剂， 反应 1.0h， 以2.3 g的产率得到Bithiazole carboxylic acid
  参考文献：
  名称：

  Potent and Orally Efficacious Bisthiazole-Based Histone Deacetylase Inhibitors

  摘要：

  Inspired by the thiazole thiazoline cap group in natural product largazole, a series of structurally simplified bisthiazole-based histone deacetylase inhibitors were prepared and evaluated. Compound 8f was evaluated in vivo in an experimental autoimmune encephalomyelitis (EAE) model and found to be orally efficacious in ameliorating clinical symptoms of EAE mice.

  DOI：

  10.1021/ml400470s

文献信息

• [EN] BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION<br/>[FR] INHIBITEURS BISTHIAZOLE DE L'ACTIVATION DE MÉTALLOPROTÉINASES DE MATRICE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2012068209A2

  公开（公告）日：2012-05-24

  This invention relates to bisthiazole I and its therapeutic and prophylactic uses, wherein the variables A, R5, R6, and R7 are defined in the specification. Disorders treated and/or prevented include rheumatoid arthritis.